Navigation Links
IVI granted 2 US patents on dysentery vaccine inventions
Date:2/27/2012

SEOUL, KOREA The International Vaccine Institute (IVI), an international organization based in Seoul devoted to research on the development and introduction of vaccines for the developing world, reached a milestone in its aim to prevent and control dysentery (also commonly called shigellosis or bloody diarrhea), a deadly disease that affects several million people worldwide. This infectious disease, caused by the bacterial pathogen Shigella, is a major health problem in developing countries, as young children are particularly vulnerable to the disease. The United States Patent and Trademark Office recently issued two patents on "Novel Shigella protein antigens and methods" to IVI. These two patents will accelerate the Institute's current efforts in developing an effective and low-cost vaccine for use among impoverished communities afflicted by dysentery.

The Shigella vaccine patents, which will expire in 2029, are the most recently issued patents of IVI. IVI filed these two patents (Applications No. 12/603,574 and No. 12/692,187) following its discovery of novel common protein antigens in several Shigella species that could be used as the basis of a universal vaccine against bacillary dysentery. With the potential to provide cross-protection across species and serotypes of Shigella, this could be the first broadly protective vaccine against dysentery. The patents claim vaccine compositions comprising either of two novel conserved Shigella proteins and a conjugate molecule comprising an O-specific polysaccharide antigen of Shigella bacteria covalently bound to either of these Shigella proteins.

Dr. Cecil Czerkinsky, IVI's Deputy Director-General of Laboratory Sciences and Dr. Dong Wook Kim, Associate Professor at Hanyang University and former IVI scientist, reported the original discovery of the Shigella common protein antigens in a provisional patent application filed in October 2008. Dr. Czerkinsky commented, "We are extremely excited about the issuance of the Shigella vaccine patents. It further reinforces our belief that these common proteins, through their immunological properties, may be highly effective in preventing shigellosis, a diarrheal disease that claims countless lives of children every year, mainly in developing countries."

"This patent issuance is an important milestone on IVI's path of delivering a new vaccine against another killer infectious disease," added Dr. Christian Loucq, IVI's Director-General. "Furthermore, it underlies the dynamism and productivity of IVI scientists."


'/>"/>

Contact: Tae Kyung Byun
tkbyun@ivi.int
82-119-773-6071
International Vaccine Institute
Source:Eurekalert

Related biology news :

1. Damon Runyon-Rachleff Innovation Awards granted for pioneering ideas in cancer research
2. Damon Runyon-Rachleff Innovation Awards granted for pioneering ideas in cancer research
3. Company Granted Patent on Apparatus, Systems, and Methods for Gathering and Processing Wireless Biometric and Biomechanical Data
4. BIO-key(R) Granted Patent for Trusted Biometric Device Security Solution
5. 2009 Damon Runyon-Rachleff Innovation Awards granted for pioneering ideas in cancer research
6. BIO-key(R) Granted Patent to Secure Biometric Enrollments From Unauthorized Use
7. BIO-key(R) Granted Additional Patent for Biometric Security Solution
8. U.S. Supreme Court petitioned to review AMP, et al. lawsuit on gene patents
9. US Patent Office affirms Zamore Design Rule patents
10. Digital data forensic expert at NJIT to be feted by R&D council for data hiding patents
11. IEEE-USA pleased that Supreme Courts ruling preserves software patents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/6/2017)... -- Delta ID Inc., a leader in consumer-grade iris scanning ... CES® 2017. Delta ID has collaborated with Gentex Corporation ... of iris scanning as a secure, reliable and convenient ... car, and as a way to elevate the security ... ID and Gentex will demonstrate (booth #7326 LVCC) a ...
(Date:12/22/2016)... 2016  As part of its longstanding mission to improve ... company, recently released its latest children,s book, titled ... on the topics of inheritance and variation of traits that ... in elementary school classrooms in the US. ... Ariana Killoran , whose previous book with 23andMe, ...
(Date:12/19/2016)... BARCELONA , España y TORONTO , 19 ... fusión con Northern Biologics Inc. que permitirá el desarrollo acelerado de ... ensayos clínicos en varios tipos de tumor en 2017, con múltiples ... ... de su clase con objetivo en el factor inhibidor de leucemia ...
Breaking Biology News(10 mins):
(Date:1/18/2017)... Jan. 18, 2017 Shareholder rights law firm ... whether the board members of CoLucid Pharmaceuticals, Inc. (NASDAQ: ... connection with the proposed sale of the Company to ... that develops small molecules for the acute treatment of ... it had signed a definitive merger agreement with Eli ...
(Date:1/18/2017)... - SQI Diagnostics Inc. (TSX-V: SQD; OTCQX: SQIDF) ... and commercializes proprietary technologies and products for advanced ... that Cameron Prange , President of Kingsdale ... Board of Directors.  Mr. Prange,s resignation is related ... limited both his ability to act on behalf ...
(Date:1/17/2017)... , ... January 17, 2017 , ... ... Balance™ GT soybeans. The new Balance™ GT Soybean Performance System will combine industry-leading ... isoxaflutole, the active ingredient in the new Balance® Bean herbicide. The Balance™ GT ...
(Date:1/17/2017)... Roka Bioscience, Inc. (NASDAQ: ROKA ), a ... detection of foodborne pathogens today announced the appointment of Mary ... Thomas , the Company,s President and CEO since 2009, who will ... The changes are effective today. In addition, Ms. Duseau ... ...
Breaking Biology Technology: